Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Worth Seeing!
Transform your wealth with Omega. Exclusive consultation awaits.Schedule Meeting!
Schedule Meeting!
Gufic Biosciences is currently trading at Rs. 231.35, up by 8.45 points or 3.79% from its previous closing of Rs. 222.90 on the BSE.
The scrip opened at Rs. 230.00 and has touched a high and low of Rs. 236.45 and Rs. 229.25 respectively. So far 27670 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 270.10 on 17-Jan-2022 and a 52 week low of Rs. 99.10 on 25-Mar-2021.
Last one week high and low of the scrip stood at Rs. 236.45 and Rs. 202.00 respectively. The current market cap of the company is Rs. 2241.84 crore.
The promoters holding in the company stood at 75.48%, while Institutions and Non-Institutions held 2.88% and 21.64% respectively.
Gufic Biosciences is entering into a research and collaboration agreement with Selvax, a biotechnology Company based in Perth, Western Australia, to accelerate the commercialization of Selvax's cancer immunotherapy treatment. Orbit Financial Capital, a boutique investment banking firm with a strong foothold in corporate finance, transaction advisory services, and debt syndication services, acts as the exclusive financial advisor to the transaction.
Under this initiative, Gufic will undertake mutually agreed development activities in return for the exclusive commercial rights for Selvax immunotherapy in India along with an equal share of future revenues that might be derived from future sales of the product in Europe, subject to the approvals received from the regulatory authorities in India and Europe, respectively. Selvax considers Gufic as an ideal collaboration partner on account of Gufic's long track record of innovation and new drug development. Gufic continues its efforts to bring innovation in the medical field by expanding its portfolio in cancer immunotherapy, which is one of the most rapidly growing segments of the global pharmaceutical market.
Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1858.70 |
| Dr. Reddys Lab | 1258.55 |
| Cipla | 1559.20 |
| Lupin | 2198.25 |
| Zydus Lifesciences | 1004.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
